Azacitidine
ONUREG is a prescription brand name for azacitidine, an oral tablet medication manufactured by Celgene Corporation. Available in 200mg and 300mg strengths, it acts as a nucleoside metabolic inhibitor to disrupt nucleic acid synthesis. This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | ONUREG is a prescription brand name for azacitidine, an oral tablet medication manufactured by Celgene Corporation. Available in 200mg and 300mg strengths, it acts as a nucleoside metabolic inhibitor to disrupt nucleic acid synthesis. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Azacitidine",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Azacitidine — ANDA 208216 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208216"
}
]
|
| identifier | ANDA208216 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"fda",
"medications",
"pharmaceuticals",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Azacitidine |
